


REMARKS

The page and line numbers referenced in the Amendment to the Specification refer to the PCT application, which is attached herein. With respect to the replacement of the phrase "and a therapeutic encapsulated compound included inside said liposomes" with the phrase "and a therapeutic compound being encapsulated inside said liposomes," the amended phrase was originally recited in the counterpart Brazilian patent application no. P 02 01 03264 and was mistranslated in the counterpart PCT application. Similarly, the recitation of the phrase "with polyethyleneglycol 750-5000, preferably polyethyleneglycol 2000" and the phrase "dipalmitoyl phosphatidylethanolamine derivatized with O-methylated polyethyleneglycol 750- 5000," in the paragraph starting at page 6, line 20 and ending at page 6, line 31, and the recitation of the phrase "following with membranes of the smallest pore size (50 nm)," in the paragraph starting at page 8, line 3 and ending at page 8, line 22, were left out during the translation. Moreover, support for these phrases exists in the claims as originally filed, such as in claims 3, 10, and 12 of the present application. Thus, no questions of new matter are raised by the above amendment. Entry of the above amendment is therefore respectfully requested.

If there are any fees due in connection with the filing of this Preliminary Amendment, please charge the fees to Deposit Account No. 50-1980. If a fee is required for an extension of time under 37 C.F.R. §1.136 not accounted for above, such extension is requested and should also be charged to our Deposit Account.

Respectfully submitted,

Date Feb. 25, 2005


Arash Behravesh (Reg. No. 45,982)

The H.T. Than Law Group
Waterfront Center
1010 Wisconsin Avenue, NW, Suite 560
Washington, DC 20007
(202) 363-2620